How do molecular aberrations guide therapy in MDS?. Issue 4 (December 2021)

• Record Type: Journal Article
• Authors: Bejar, Rafael
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 34:Issue 4(2021)
• Publication Date: 2021-12
• Subjects: Hypomethylating agents -- HMAs -- Lenalidomide -- Myelodysplastic syndromes -- MDS -- Splicing factor 3b subunit 1 -- SF3B1 -- Ten-eleven translocation-2 -- TET2 -- TP53; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2021.101324
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: Myelodysplastic syndromes (MDS) represent a cluster of genetically and phenotypically heterogeneous hematological disorders. While molecularly targeted therapies have entered the standard of care for other hematological malignancies like acute myeloid leukemia, this approach has been elusive in MDS. This review has summarized recent evidence to determine how molecular aberrations can be used to guide therapy in MDS and improve outcomes among patients.